Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury

Experimental and Molecular Pathology

Volumn 94, Issue 2, 2013, Pages 352-359

  Zaouali, Mohamed Amine ^a   Bardag Gorce, Fawzia ^b   Carbonell, Teresa ^c   Oliva, Joan ^b   Pantazi, Eirini ^a   Bejaoui, Mohamed ^a   Abdennebi, Hassen Ben ^d   Rimola, Antoni ^e   Roselló Catafau, Joan ^a,e  

^a CSIC   (Spain)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF MONASTIR   (Tunisia)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Bortezomib; Ischemia reperfusion injury; MG132; Steatotic liver; UPS inhibitor; UW preservation solution

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CHYMOTRYPSIN; GLUTAMATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; UNIVERSITY OF WISCONSIN SOLUTION;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE; COLD ISCHEMIA; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE RELEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY LIVER; LIVER INJURY; LIVER TRANSPLANTATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY; VASCULAR RESISTANCE;

ADIPONECTIN; ANIMALS; BORONIC ACIDS; COLD ISCHEMIA; CYSTEINE PROTEINASE INHIBITORS; CYTOPROTECTION; FATTY LIVER; INTERLEUKIN-1; LEUPEPTINS; LIVER TRANSPLANTATION; MITOCHONDRIA, LIVER; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; OXIDATIVE STRESS; PROTEASOME INHIBITORS; PYRAZINES; RATS; RATS, ZUCKER; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874481750     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.12.005     Document Type: Article

References (45)

1. Alexandrova A., Petrov L., Georgieva A., Kessiova M., Tzvetanova E., Kirkova M., Kukan M. Effect of MG132 on proteasome activity and prooxidant/antioxidant status of rat liver subjected to ischemia/reperfusion injury. Hepatology Research 2008, 38:393-401.
2. Baker T.A., Geng Q., Romero J., Picken M.M., Gamelli R.L., Majetschak M. Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation. Biochemical and Biophysical Research Communications 2010, 401:548-553.
3. Bardag-Gorce F. Proteasome inhibitor treatment in alcoholic liver disease. World Journal of Gastroenterology 2011, 17:2558-2562.
4. Bardag-Gorce F., Oliva J., Lin A., Li J., French B.A., French S.W. Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease. Experimental and Molecular Pathology 2011, 90:123-130.
5. Bedford L., Lowe J., Dick L.R., Mayer R.J., Brownell J.E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature Reviews. Drug Discovery 2011, 10:29-46.
6. Ben Abdennebi H., Zaouali M.A., Alfany-Fernandez I., Tabka D., Rosello-Catafau J. How to protect liver graft with nitric oxide. World Journal of Gastroenterology 2011, 17:2879-2889.
7. Ben Mosbah I., Rosello-Catafau J., Franco-Gou R., Abdennebi H.B., Saidane D., Ramella-Virieux S., Boillot O., Peralta C. Preservation of steatotic livers in IGL-1 solution. Liver Transplantation 2006, 12:1215-1223.
8. Ben Mosbah I., Massip-Salcedo M., Fernandez-Monteiro I., Xaus C., Bartrons R., Boillot O., Rosello-Catafau J., Peralta C. Addition of adenosine monophosphate-activated protein kinase activators to University of Wisconsin solution: a way of protecting rat steatotic livers. Liver Transplantation 2007, 13:410-425.
9. Bouma H.R., Ketelaar M.E., Yard B.A., Ploeg R.J., Henning R.H. AMP-activated protein kinase as a target for preconditioning in transplantation medicine. Transplantation 2010, 90:353-358.
10. Busuttil R.W., Tanaka K. The utility of marginal donors in liver transplantation. Liver Transplantation 2003, 9:651-663.
11. Caldwell S.H., Swerdlow R.H., Khan E.M., Iezzoni J.C., Hespenheide E.E., Parks J.K., Parker W.D. Mitochondrial abnormalities in non-alcoholic steatohepatitis. Journal of Hepatology 1999, 31:430-434.
12. Campbell B., Adams J., Shin Y.K., Lefer A.M. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. Journal of Molecular and Cellular Cardiology 1999, 31:467-476.
13. Carrasco-Chaumel E., Rosello-Catafau J., Bartrons R., Franco-Gou R., Xaus C., Casillas A., Gelpi E., Rodes J., Peralta C. Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation. Journal of Hepatology 2005, 43:997-1006.
14. Farrell G.C., Teoh N.C., McCuskey R.S. Hepatic microcirculation in fatty liver disease. Anatomical Record (Hoboken, N.J.: 2007) 2008, 291:684-692.
15. Groll M., Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochimica et Biophysica Acta 2004, 1695:33-44.
16. Hattori Y., Suzuki K., Hattori S., Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47:1183-1188.
17. Imber C.J., St Peter S.D., Handa A., Friend P.J. Hepatic steatosis and its relationship to transplantation. Liver Transplantation 2002, 8:415-423.
18. Jing H., Shen G., Wang G., Zhang F., Li Y., Luo F., Yao J., Tian X.F. MG132 alleviates liver injury induced by intestinal ischemia/reperfusion in rats: involvement of the AhR and NFkappaB pathways. The Journal of Surgical Research 2012, 176(1):63-73.
19. Klar E., Angelescu M., Zapletal C., Kraus T., Bredt M., Herfarth C. Definition of maximum cold ischemia time without reduction of graft quality in clinical liver transplantation. Transplantation Proceedings 1998, 30:3683-3685.
20. Kloss A., Meiners S., Ludwig A., Dahlmann B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovascular Research 2010, 85:367-375.
21. Majetschak M., Patel M.B., Sorell L.T., Liotta C., Li S., Pham S.M. Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochemical and Biophysical Research Communications 2008, 365:882-888.
22. Massip-Salcedo M., Zaouali M.A., Padrissa-Altes S., Casillas-Ramirez A., Rodes J., Rosello-Catafau J., Peralta C. Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion. Hepatology 2008, 47:461-472.
23. McCormack L., Dutkowski P., El-Badry A.M., Clavien P.A. Liver transplantation using fatty livers: always feasible?. Journal of Hepatology 2011, 54:1055-1062.
24. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:10403-10408.
25. Moore B.S., Eustaquio A.S., McGlinchey R.P. Advances in and applications of proteasome inhibitors. Current Opinion in Chemical Biology 2008, 12:434-440.
26. Peralta C., Rosello-Catafau J. The future of fatty livers. Journal of Hepatology 2004, 41:149-151.
27. Phillips J.B., Williams A.J., Adams J., Elliott P.J., Tortella F.C. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 2000, 31:1686-1693.
28. Powell S.R., Wang P., Katzeff H., Shringarpure R., Teoh C., Khaliulin I., Das D.K., Davies K.J., Schwalb H. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxidants & Redox Signaling 2005, 7:538-546.
29. Ramalho F.S., Fernandez-Monteiro I., Rosello-Catafau J., Peralta C. Hepatic microcirculatory failure. Acta Cirúrgica Brasileira 2006, 21(Suppl. 1):48-53.
30. Rashid A., Wu T.C., Huang C.C., Chen C.H., Lin H.Z., Yang S.Q., Lee F.Y., Diehl A.M. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999, 29:1131-1138.
31. Selzner M., Clavien P.A. Fatty liver in liver transplantation and surgery. Seminars in Liver Disease 2001, 21:105-113.
32. Stratta R.J., Wood R.P., Langnas A.N., Duckworth R.M., Markin R.S., Marujo W., Grazi G.L., Saito S., Dawidson I., Rikkers L.F., et al. The impact of extended preservation on clinical liver transplantation. Transplantation 1990, 50:438-443.
33. Takaoka M., Itoh M., Kohyama S., Shibata A., Ohkita M., Matsumura Y. Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats. Journal of Cardiovascular Pharmacology 2000, 36:S225-S227.
34. Todo S., Demetris A.J., Makowka L., Teperman L., Podesta L., Shaver T., Tzakis A., Starzl T.E. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989, 47:903-905.
35. Todo S., Nery J., Yanaga K., Podesta L., Gordon R.D., Starzl T.E. Extended preservation of human liver grafts with UW solution. JAMA: The Journal of the American Medical Association 1989, 261:711-714.
36. Vairetti M., Ferrigno A., Carlucci F., Tabucchi A., Rizzo V., Boncompagni E., Neri D., Gringeri E., Freitas I., Cillo U. Subnormothermic machine perfusion protects steatotic livers against preservation injury: a potential for donor pool increase?. Liver Transplantation 2009, 15:20-29.
37. Yang Y.M., Han C.Y., Kim Y.J., Kim S.G. AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability. World Journal of Gastroenterology 2010, 16:3731-3742.
38. Yu X., Kem D.C. Proteasome inhibition during myocardial infarction. Cardiovascular Research 2010, 85:312-320.
39. Zaouali M.A., Ben Abdennebi H., Padrissa-Altes S., Mahfoudh-Boussaid A., Rosello-Catafau J. Pharmacological strategies against cold ischemia reperfusion injury. Expert Opinion on Pharmacotherapy 2010, 11:537-555.
40. Zaouali M.A., Ben Mosbah I., Padrissa-Altes S., Calvo M., Ben Abdennebi H., Saidane-Mosbahi D., Bjaoui M., Garcia-Gil F.A., Panisello A., Rosello-Catafau J. Relevance of epidermal growth factor to improve steatotic liver preservation in IGL-1 solution. Transplantation Proceedings 2010, 42:3070-3075.
41. Zaouali M.A., Padrissa-Altes S., Ben Mosbah I., Alfany-Fernandez I., Massip-Salcedo M., Casillas-Ramirez A., Bintanel-Morcillo M., Boillot O., Serafin A., Rimola A., Rodes J., Rosello-Catafau J., Peralta C. Improved rat steatotic and nonsteatotic liver preservation by the addition of epidermal growth factor and insulin-like growth factor-I to University of Wisconsin solution. Liver Transplantation 2010, 16:1098-1111.
42. Zaouali M.A., Padrissa-Altes S., Ben Mosbah I., Ben Abdennebi H., Boillot O., Rimola A., Saidane-Mosbahi D., Rosello-Catafau J. Insulin like growth factor-1 increases fatty liver preservation in IGL-1 solution. World Journal of Gastroenterology 2010, 16:5693-5700.
43. Zaouali M.A., Reiter R.J., Padrissa-Altes S., Boncompagni E., Garcia J.J., Ben Abnennebi H., Freitas I., Garcia-Gil F.A., Rosello-Catafau J. Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. Journal of Pineal Research 2011, 50:213-221.
44. Zhang L., Zhang Z.G., Liu X., Hozeska A., Stagliano N., Riordan W., Lu M., Chopp M. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thrombosis and Haemostasis 2006, 95:166-173.
45. Zungu M., Schisler J.C., Essop M.F., McCudden C., Patterson C., Willis M.S. Regulation of AMPK by the ubiquitin proteasome system. The American Journal of Pathology 2011, 178:4-11.